Bristol-Myers Squibb Co Announces Quarterly Dividend of $0.40 (BMY)

Share on StockTwits

Bristol-Myers Squibb Co (NYSE:BMY) announced a quarterly dividend on Thursday, June 14th, RTT News reports. Shareholders of record on Friday, July 6th will be paid a dividend of 0.40 per share by the biopharmaceutical company on Wednesday, August 1st. This represents a $1.60 annualized dividend and a yield of 2.98%.

Bristol-Myers Squibb has raised its dividend by an average of 2.7% annually over the last three years and has increased its dividend annually for the last 8 consecutive years. Bristol-Myers Squibb has a dividend payout ratio of 53.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Bristol-Myers Squibb to earn $3.64 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 44.0%.

Bristol-Myers Squibb traded up $0.17, hitting $53.63, during mid-day trading on Thursday, MarketBeat Ratings reports. 4,736,363 shares of the company’s stock traded hands, compared to its average volume of 8,432,290. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.52 and a quick ratio of 1.39. The company has a market capitalization of $86.83 billion, a P/E ratio of 17.82, a PEG ratio of 1.39 and a beta of 0.95. Bristol-Myers Squibb has a one year low of $49.96 and a one year high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. The firm had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.84 EPS. research analysts expect that Bristol-Myers Squibb will post 3.43 earnings per share for the current fiscal year.

In related news, Director Dinesh C. Paliwal bought 4,770 shares of the business’s stock in a transaction dated Monday, April 30th. The shares were bought at an average cost of $52.40 per share, with a total value of $249,948.00. Following the completion of the transaction, the director now directly owns 8,027 shares of the company’s stock, valued at $420,614.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.12% of the stock is owned by insiders.

BMY has been the topic of several recent analyst reports. Jefferies Financial Group set a $72.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 26th. Bank of America lifted their target price on Bristol-Myers Squibb from $64.00 to $68.00 and gave the company a “neutral” rating in a research note on Monday, March 5th. Barclays cut their target price on Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Friday, April 27th. ValuEngine downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Finally, JPMorgan Chase & Co. set a $75.00 price objective on Bristol-Myers Squibb and gave the stock an “overweight” rating in a research note on Tuesday, March 20th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $62.84.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Dividend History for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Axiom Price Reaches $0.0078 on Exchanges
Axiom Price Reaches $0.0078 on Exchanges
Starta Hits 24-Hour Trading Volume of $0.00
Starta Hits 24-Hour Trading Volume of $0.00
Zacks: Brokerages Expect MTS Systems Co.  Will Announce Earnings of $0.63 Per Share
Zacks: Brokerages Expect MTS Systems Co. Will Announce Earnings of $0.63 Per Share
Obalon Therapeutics  Getting Somewhat Positive Media Coverage, Study Shows
Obalon Therapeutics Getting Somewhat Positive Media Coverage, Study Shows
Novus Therapeutics  Receives News Impact Score of 0.16
Novus Therapeutics Receives News Impact Score of 0.16
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc  This Quarter
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc This Quarter


Leave a Reply

 
© 2006-2018 Zolmax.